Citadel Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
|
|||||
|
2024
Q1 | $411K | Buy |
|
|||||
|
2023
Q2 | – | Sell |
|
|||||
|
2023
Q1 | $312K | Buy |
|
|||||
|
2022
Q4 | $187K | Sell |
|
|||||
|
2022
Q3 | $305K | Buy |
|
|||||
|
2022
Q2 | – | Sell |
|
|||||
|
2022
Q1 | $257K | Buy |
|
|||||
|
2021
Q3 | – | Sell |
|
|||||
|
2021
Q2 | $1.5M | Buy |
|
|||||
|
2021
Q1 | $1.27M | Buy |
|
|||||
|
2020
Q4 | $290K | Sell |
|
|||||
|
2020
Q3 | $675K | Buy |
|
|||||
|
2020
Q2 | $588K | Sell |
|
|||||
|
2020
Q1 | $450K | Sell |
|
|||||
|
2019
Q4 | $818K | Sell |
|
|||||
|
2019
Q3 | $743K | Buy |
|
|||||
|
2019
Q2 | $771K | Buy |
|
|||||
|
2019
Q1 | $712K | Buy |
|
|||||
|
2017
Q1 | – | Sell |
|
|||||
|
2016
Q4 | $257K | Buy |
|
|||||
|
2016
Q2 | – | Sell |
|
|||||
|
2016
Q1 | $220K | Buy |
|